Clonal Hematopoiesis

Definition

Clonal hematopoiesis (CH) refers to the disproportionate but benign expansion of hematopoietic stem cell (HSC) clones driven by somatic mutations in genes associated with hematologic malignancies. CHIP (clonal hematopoiesis of indeterminate potential) is the formal term when a leukemia-associated variant is present at variant allele frequency (VAF) ≥2% without cytopenia, dysplasia, or neoplasia — a WHO-recognized pre-malignant condition. CH is near-ubiquitous in adults >70 years and has emerged as a convergent risk factor for both hematologic malignancy and a broad spectrum of cardiovascular diseases.

Key Concepts

Epidemiology and Definition Thresholds

• VAF ≥2% (CHIP threshold) corresponds to >4% of circulating blood cells from one clone (assuming heterozygosity, neutral copy number). Error-corrected sequencing reveals that CH driver variants arise early in life and are near-universal in adults >70. (sources/ch-aha-2026, rating: very high)
• ~10% of adults >70 years have CHIP at VAF ≥2% by standard whole-exome sequencing. (sources/ch-aha-2026)
• Clonal cytopenia of undetermined significance: unexplained persistent cytopenias with CHIP variants — also WHO pre-malignant. (sources/ch-aha-2026)
• CH risk score stratifies myeloid malignancy progression risk: high risk = >50% blood cancer in 10 years; low risk = <1% in 10 years. Post-hoc analyses also predict CVD-related death. (sources/ch-aha-2026)
• CH is associated with a 40–50% increase in all-cause mortality, attributable largely to increased CVD risk. (sources/ch-aha-2026)
• The three most frequently mutated driver genes are DNMT3A, TET2, and ASXL1 — each associated with increased ASCVD. (sources/ch-aha-2026, sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)

Risk Factors for CH

Age and Germline Predisposition

• Age is the dominant risk factor. (sources/ch-aha-2026)
• Germline variants: TERT variant (OR 1.3, most prominent — encodes telomerase reverse transcriptase); ATM (OR 1.46, DNA damage response); PARP1 (OR 0.87, protective). TCL1A promoter variant protects against TET2/ASXL1 CH but predisposes to DNMT3A CH. (sources/ch-aha-2026)
• Rare pathogenic variants in RUNX1/CHEK2/ATM/TINF2/PTPN11 → 2–10× CH risk. Down syndrome increases early-onset CH risk. (sources/ch-aha-2026)

Therapy-Related CH (t-CH)

• Cytotoxic chemotherapy selects for DDR pathway variants (TP53, PPM1D, CHEK2, ATM) under genotoxic stress. t-CH prevalence up to 30% in relatively young cancer survivors. (sources/ch-aha-2026)
• Radiation → 2–4× increased CH risk, dependent on modality and intensity. (sources/ch-aha-2026)
• Smoking increases ASXL1-CH specifically. (sources/ch-aha-2026)

Chronic Inflammation

• HIV infection, premature menopause (estrogen loss), obesity, sleep deprivation all promote CH via chronic inflammation and oxidative stress. (sources/ch-aha-2026)
• Healthy diet is protective against CH risk. (sources/ch-aha-2026)
• Ancestry: CH frequency is 1.6-fold lower in a Mexican cohort vs. UK Biobank; JAK2 CH is especially reduced — genetic and environmental contributions not yet separated. (sources/ch-aha-2026)

CH and Cardiovascular Disease Outcomes

ASCVD

• DNMT3A/TET2/ASXL1 CH → 1.7–2× higher ASCVD risk vs. non-carriers; higher CAC scores; CH 4-fold enriched in early-onset MI. (sources/ch-aha-2026, sources/cardio-oncology-vascular-metabolic-aha-2019, rating: very high)
• CH worsens outcomes after MI and after cardiogenic shock. (sources/ch-aha-2026)
• Larger clones (VAF ≥10%) and TET2/JAK2 variants carry the greatest ASCVD risk. Association with recurrent ASCVD events in established disease is inconsistent across datasets. (sources/ch-aha-2026)

Heart Failure

• Meta-analysis of 56,597 individuals without baseline HF → 25% higher HF risk in CH carriers, independent of traditional risk factors and CAD. (sources/ch-aha-2026)
• CH not significantly associated with overall HFrEF/HFpEF, but gene-specific: TET2 variants 2.4-fold enriched in HFpEF; ASXL1 associated with modestly reduced EF. (sources/ch-aha-2026)
• CH in patients with established HF → higher all-cause mortality, HF-related hospitalisations. (sources/ch-aha-2026)

Broader CVD

• CH associated with AF, stroke, PAD, aortopathy, myocarditis, and worse outcomes after aortic valve interventions. (sources/ch-aha-2026)
• JAK2 V617F specifically linked to increased arterial and venous thrombosis. (sources/ch-aha-2026)

Gene-Specific Mechanisms

TET2

• TET2 LOF → overactivation of NLRP3 inflammasome → increased IL-1β secretion (heightened histone acetylation at Il1β promoter). (sources/ch-aha-2026)
• Humans with somatic TET2 variants have elevated circulating IL-1β — not seen with other CH variants. (sources/ch-aha-2026)
• IL6R D358A germline variant (reduces IL-6 signalling) mitigates the elevated CAD risk of TET2-CH carriers. (sources/ch-aha-2026)
• CANTOS post-hoc: canakinumab (anti-IL-1β) reduced ischemic events far more in TET2-CH carriers than in non-CH individuals. (sources/ch-aha-2026)
• Colchicine mitigates TET2-CH–driven atherosclerosis in mouse models. (sources/ch-aha-2026)
• Vitamin C may restore TET2 function — under investigation. (sources/ch-aha-2026)

DNMT3A

• LOF → similar but milder proinflammatory cytokine/chemokine profile vs. TET2; distinct tissue-resident-like macrophage populations. (sources/ch-aha-2026)
• Impairs efferocytosis in atherosclerotic plaques → adverse plaque remodeling. (sources/ch-aha-2026)
• Increases secretion of HB-EGF (heparin-binding epidermal growth factor-like growth factor) → cardiac fibrosis. (sources/ch-aha-2026)
• Metformin proposed to reduce DNMT3A-variant clonal fitness — under investigation. (sources/ch-aha-2026)

ASXL1

• Truncating variants in C-terminal exon → truncated protein (distinct from TET2/DNMT3A LOF). (sources/ch-aha-2026)
• Promotes inflammation and cardiac remodelling post-LAD ligation in mice. Accelerates atherosclerosis via enhanced myeloid cell inflammation. (sources/ch-aha-2026)
• Gene-specific: ASXL1 CH associated with modestly reduced EF in HF cohort studies. (sources/ch-aha-2026)

JAK2 V617F

• Common myeloproliferative neoplasm driver; associated with CVD risk even without elevated blood cell counts (identified in 3–4% of general European population by droplet digital PCR). (sources/ch-aha-2026)
• Mechanisms: increased platelet activation, polycythemia, NET formation → thrombosis; myeloid cell and myocardial inflammation → HF; NLRP3/AIM2 inflammasome activation, impaired efferocytosis → atherosclerosis; thoracic aortic aneurysm in mouse models. (sources/ch-aha-2026)

Therapy-Related CH (TP53, PPM1D, CHEK2, ATM)

• TP53-CH is amplified by doxorubicin (promotes Tp53-variant HSC expansion) → worse anthracycline-induced cardiomyopathy in mouse models. (sources/ch-aha-2026)
• PPM1D-CH → increased IL-1β + myocardial fibrosis after angiotensin II infusion in mice; effects reversed by NLRP3 inhibitor. (sources/ch-aha-2026)
• Shared mechanism with canonical CH genes: all t-CH variants tested amplify IL-1β expression. (sources/ch-aha-2026)

Clinical Translation

• No official CH screening guidelines exist. CH is currently identified incidentally (hereditary cancer panels, liquid biopsy from solid tumour evaluation, haematology panels for abnormal counts). (sources/ch-aha-2026)
• CHIP clinics at tertiary centres provide multidisciplinary surveillance primarily focused on haematologic malignancy risk; CV risk evaluated by cardio-oncology. (sources/ch-aha-2026)
• CVD risk management: Current risk models (PREVENT, SCORE2) do not incorporate CH. Guideline-concordant primary and secondary prevention is the recommended approach until CH-specific CVD therapies are proven. (sources/ch-aha-2026)
• Emerging therapeutic strategies (not yet proven in prospective CVD trials):
  • Vitamin C — may restore TET2 function
  • Metformin — may reduce DNMT3A-variant clonal fitness
  • Colchicine — mitigates TET2-CH atherosclerosis (preclinical + indirect CANTOS data)
  • Canakinumab/NLRP3 inhibitors — benefit in TET2-CH (CANTOS post-hoc only)

Contradictions / Open Questions

• Causality vs. association for CVD: Whether CH is a direct causal driver of CVD, an associative marker of biological aging, or both, remains under active investigation across all outcomes. (sources/ch-aha-2026)
• CH-ASCVD directionality: Computational modeling suggested ASCVD itself may drive CH (feedback via hematopoietic response to atherosclerosis). However, longitudinal studies combining serial CH assessment with atherosclerosis imaging demonstrate that atherosclerosis does not appear to drive CH development — favouring a unidirectional CH → ASCVD relationship. (sources/ch-aha-2026)
• Systemic vs. local mechanisms in CVD: The relative importance of systemic cytokine effects of variant immune cells vs. direct effects within the myocardium or atherosclerotic plaque remains unclear in humans. Y-chromosome–deficient cardiac macrophages activate profibrotic signalling in mice, but human data are lacking. (sources/ch-aha-2026)
• CH-ASCVD association inconsistency in lower-risk populations: The CH-ASCVD relationship is inconsistent in the UK Biobank (lower-risk population), likely due to variability in CH definition, VAF calling thresholds, and population heterogeneity. (sources/ch-aha-2026)
• CANTOS IL-1β benefit was post-hoc and not powered for TET2-CH subgroup: The therapeutic implication (IL-1β targeting in TET2-CH) is biologically compelling but requires a prospective CH-enriched trial to confirm. (sources/ch-aha-2026)
• No CH-targeted CVD therapy proven. Multiple hypotheses (vitamin C, metformin, colchicine, IL-1β inhibitors) are under investigation but no prospective CVD-outcome trial in a CH-enriched cohort has been completed. (sources/ch-aha-2026)
• The mechanisms by which DNMT3A/ASXL1 mutations drive atherosclerosis are less elucidated than TET2 — macrophage-centric hypothesis is leading but molecular regulatory pathways remain to be determined. (sources/ch-aha-2026, sources/cardio-oncology-vascular-metabolic-aha-2019)

Connections

• Related to concepts/Cardio-Oncology — CH as emerging shared cancer-CVD risk factor; CHIP clinics
• Related to concepts/Cancer-Therapy-Related-CV-Toxicity — t-CH amplifies late cardiotoxicity from anthracyclines; TP53/PPM1D mechanisms
• Related to concepts/ASCVD-Risk-Assessment — CH not yet incorporated in PREVENT or SCORE2 models; emerging integration
• Related to entities/Heart-Failure — 25% higher HF risk; TET2 2.4× in HFpEF; ASXL1 → reduced EF
• Related to entities/Atrial-Fibrillation — CH associated with AF risk
• Related to sources/ch-aha-2026
• Related to sources/cardio-oncology-vascular-metabolic-aha-2019

Sources

• sources/cardio-oncology-vascular-metabolic-aha-2019
• sources/ch-aha-2026